Tacrolimus 0.1% versus ciclopiroxolamine 1% for maintenance therapy in patients with severe facial seborrheic dermatitis : a multicenter, double-blind, randomized controlled study - Supplementary Appendix

Published: 24 September 2020| Version 1 | DOI: 10.17632/y3hmp9nbty.1
Contributors:
Ines TEJEDOR,
Pascal Joly

Description

Supplementary Appendix

Files

Categories

Seborrheic Dermatitis

License